Australia's most trusted
source of pharma news
Friday, 08 August 2025
Posted 5 August 2025 AM
The time between TGA approval and PBS listing has increased again, to a new record average of 679 days before patients get access to the medicines.
Amgen's Australian Patient Access Gap Tracker measures the average patient access gap (PAG) in days for innovative medicines and population pairings, covering those that were recommended by the PBAC from January 2021 onwards and subsequently listed. It includes 241 medicine and population listings recommended over 29 meetings.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.